Fig. 6.

hPG80 kinetics in patients receiving cancer treatments in the PRO-RENAPE cohort. Changes in hPG80 concentrations from baseline to post-operative time (8–24 h after surgery) in patients with peritoneal carcinomatoses from gastrointestinal cancers treated with cytoreductive surgery, with or without peri-operative chemotherapy. (A) hPG80 level changes at the population level (Baseline, n = 194; End of surgery, n = 85; p < 0.0001 with two-tailed Mann–Whitney U). (B) hPG80 level changes at individual levels. The left part of the Figure represents patients with decrease hPG80 between baseline and end of surgery (n = 46) and the right part of the Figure represents patients with stable or increase hPG80 (n = 16) between baseline and end of surgery (p < 0.0001 with Wilcoxon signed-rank). The table shows the proportions of patients who had hPG80 decline >25%, stable levels, and hPG80 increase >25%.